Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

HFrEF, HFpEF and what ejection fraction means

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Ejection fraction is the number people fixate on, and it is genuinely important: it decides which treatments are proven to help.

It is also widely misunderstood. A normal ejection fraction does not mean the heart is fine, and a low one does not map neatly onto how unwell someone feels.

Related pages: Heart failure

The bottom line

What we know
  • Ejection fraction is the percentage of blood pumped out of the left ventricle per beat.
  • Normal is roughly 50 to 70 percent.
  • HFrEF is 40 percent or below; mildly reduced is 41 to 49; preserved is 50 or above.
  • About half of heart failure is the preserved type.
  • Symptoms and NYHA class correlate poorly with ejection fraction.
What is still open
  • Whether HFpEF is a single condition or several distinct ones.
  • The best treatment strategy for HFpEF beyond SGLT2 inhibitors.
  • Whether the EF cut-offs are drawn in the right places.

The story, step by step

  1. 1. The measurement ()
  2. 2. Reduced ()
  3. 3. Preserved ()
  4. 4. The other scales ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 4

What EF is and is not

Review of many studies

What happens

A fraction, not a volume.

What the research shows

  • The left ventricle never empties completely. Ejection fraction is the proportion of its contents ejected with each beat.
  • It is usually measured on an echocardiogram, and can also come from cardiac MRI, which is more accurate, or from a nuclear scan.
  • Echo measurement has meaningful variability between operators, so a change from 45 to 40 may be measurement noise rather than deterioration.
  • EF does not measure how much blood the heart actually delivers. A dilated ventricle with a low EF can pump a normal volume.
  • Nor does it track symptoms well. People with an EF of 25 can walk several miles, and people with a normal EF can be severely limited.
  • It matters mainly because the major treatment trials selected patients by EF, so the evidence is organised around it.

Why it matters

EF is a treatment-selection tool more than a severity score. Treating the number as a verdict on how sick someone is misreads what it measures.

What's still uncertain

  • How much echo-to-echo variability affects treatment decisions.
  • Whether other measures such as global longitudinal strain should replace it.

Read more

Next: Reduced

Part 2 of 4

HFrEF, 40 percent or below

Review of many studies

What happens

The weak-squeeze type.

What the research shows

  • The muscle is damaged or weakened, most often by a previous heart attack, long-standing high blood pressure, or a cardiomyopathy.
  • The ventricle typically enlarges and changes shape, a process called remodelling, which makes the pumping less efficient still.
  • This is the type with the strongest evidence base, because most major trials enrolled these patients.
  • Four drug classes improve survival, and devices help some people further.
  • Ejection fraction can improve substantially on full treatment, and in some people returns to normal, now described as heart failure with improved ejection fraction.
  • Treatment continues even when EF improves, because stopping it frequently leads to relapse.

Why it matters

The improved-EF group is important and often misunderstood: feeling well and having a normal EF again is a reason to continue treatment, not to stop it.

What's still uncertain

  • How long treatment must continue after EF recovery.
  • Who can safely reduce therapy.

Read more

Next: Preserved

Part 3 of 4

HFpEF, 50 percent or above

Review of many studies

What happens

The stiff-fill type.

What the research shows

  • The ventricle squeezes normally but is thick and stiff, so it fills poorly and at high pressure.
  • That high filling pressure is transmitted back into the lungs, producing the same breathlessness as the reduced type.
  • It is strongly associated with ageing, high blood pressure, obesity, diabetes, atrial fibrillation, kidney disease and sleep apnea.
  • Diagnosis is harder, because the echo looks nearly normal. It relies on symptoms, natriuretic peptides, measures of diastolic function and sometimes exercise testing.
  • For decades no treatment improved outcomes. SGLT2 inhibitors changed that, reducing hospital admissions and cardiovascular death.
  • Treating the associated conditions, particularly blood pressure, weight, atrial fibrillation and sleep apnea, remains central.

Why it matters

HFpEF is now about half of all heart failure and was for a long time the half with almost nothing proven to offer. That has only recently changed.

What's still uncertain

  • Whether HFpEF comprises several distinct conditions.
  • Which additional treatments will prove effective.

Read more

Next: The other scales

Part 4 of 4

NYHA class and ACC/AHA stage

Review of many studies

What happens

Two different things, often confused.

What the research shows

  • New York Heart Association class describes current symptoms. Class I: no limitation. II: slight limitation with ordinary activity. III: marked limitation with less than ordinary activity. IV: symptoms at rest.
  • NYHA class moves up and down with treatment and with fluid status. Someone can be class III on admission and class II a week later.
  • The ACC/AHA stages describe disease progression and do not move backwards. Stage A: at risk, no structural disease. Stage B: structural disease, no symptoms. Stage C: structural disease with current or past symptoms. Stage D: advanced, symptoms despite full treatment.
  • Stages A and B are where prevention happens, and most people in them do not know they are there.
  • Clinicians use both: the stage for the long view, the class for how someone is right now.
  • Being told stage C sounds alarming and simply means symptoms have occurred at some point, which is true of almost everyone diagnosed.

Why it matters

Hearing stage C or class III without the explanation causes a lot of unnecessary alarm. They answer different questions, and only one of them can improve.

What's still uncertain

  • How well NYHA class is applied consistently between clinicians.
  • Whether the stages usefully guide preventive treatment in practice.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.